Published in Curr Med Chem on January 01, 2008
Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci (2010) 3.61
O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress. Biochim Biophys Acta (2009) 2.64
Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov (2009) 2.08
Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol (2008) 1.78
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med (2011) 1.68
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62
Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain (2009) 1.48
Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov (2009) 1.45
Multi-target drugs: the trend of drug research and development. PLoS One (2012) 1.28
Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol (2012) 1.26
Regulation of mitochondrial respiratory chain biogenesis by estrogens/estrogen receptors and physiological, pathological and pharmacological implications. Biochim Biophys Acta (2009) 1.26
Sodium selenate mitigates tau pathology, neurodegeneration, and functional deficits in Alzheimer's disease models. Proc Natl Acad Sci U S A (2010) 1.24
Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. J Neurosci (2010) 1.23
Cdk5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex. J Neurosci (2010) 1.21
Tissue-nonspecific alkaline phosphatase promotes the neurotoxicity effect of extracellular tau. J Biol Chem (2010) 1.15
Hyperphosphorylated Tau in an α-synuclein-overexpressing transgenic model of Parkinson's disease. Eur J Neurosci (2011) 1.14
Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties. Genes Nutr (2009) 1.12
Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem (2009) 1.08
Zileuton improves memory deficits, amyloid and tau pathology in a mouse model of Alzheimer's disease with plaques and tangles. PLoS One (2013) 1.05
Tau and tauopathies. Prog Mol Biol Transl Sci (2012) 1.04
What Renders TAU Toxic. Front Neurol (2013) 1.00
Alzheimer's disease and anesthesia. Front Neurosci (2011) 1.00
Structure and pathology of tau protein in Alzheimer disease. Int J Alzheimers Dis (2012) 0.96
Mitochondrial superoxide contributes to blood flow and axonal transport deficits in the Tg2576 mouse model of Alzheimer's disease. PLoS One (2010) 0.94
Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. J Clin Immunol (2014) 0.93
Molecular chaperones and regulation of tau quality control: strategies for drug discovery in tauopathies. Future Med Chem (2011) 0.92
Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS One (2012) 0.91
Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci (2014) 0.91
SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination. Proc Natl Acad Sci U S A (2014) 0.90
TOC1: characterization of a selective oligomeric tau antibody. J Alzheimers Dis (2013) 0.89
Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer's disease donor as a model for investigating AD-associated gene regulatory networks. BMC Genomics (2015) 0.89
Mitochondrial dynamics in cancer and neurodegenerative and neuroinflammatory diseases. Int J Cell Biol (2012) 0.88
The 12-15-lipoxygenase is a modulator of Alzheimer's-related tau pathology in vivo. Aging Cell (2013) 0.87
The influence of 5-lipoxygenase on Alzheimer's disease-related tau pathology: in vivo and in vitro evidence. Biol Psychiatry (2013) 0.87
From chronic cerebral hypoperfusion to Alzheimer-like brain pathology and neurodegeneration. Cell Mol Neurobiol (2014) 0.86
Transgenic animal models of neurodegeneration based on human genetic studies. J Neural Transm (Vienna) (2010) 0.85
Deregulation of protein phosphatase 2A and hyperphosphorylation of τ protein following onset of diabetes in NOD mice. Diabetes (2012) 0.85
The CDK5 repressor CDK5RAP1 is a methylthiotransferase acting on nuclear and mitochondrial RNA. Nucleic Acids Res (2012) 0.85
Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy. Int J Alzheimers Dis (2012) 0.84
Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP. J Mol Biol (2010) 0.83
Allopregnanolone and neurogenesis in the nigrostriatal tract. Front Cell Neurosci (2014) 0.83
Activation of mTOR: a culprit of Alzheimer's disease? Neuropsychiatr Dis Treat (2015) 0.83
Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease. ACS Chem Neurosci (2014) 0.82
Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease. Curr Alzheimer Res (2012) 0.82
Natural products as a rich source of tau-targeting drugs for Alzheimer's disease. Future Med Chem (2012) 0.82
Blockade of NR2A-containing NMDA receptors induces Tau phosphorylation in rat hippocampal slices. Neural Plast (2010) 0.82
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease. Biomed Res Int (2016) 0.81
Mitochondrial dysfunction and oxidative stress in aging and cancer. Oncotarget (2016) 0.80
The cell cycle regulator phosphorylated retinoblastoma protein is associated with tau pathology in several tauopathies. J Neuropathol Exp Neurol (2011) 0.80
Roles of tau protein in health and disease. Acta Neuropathol (2017) 0.80
Neuronal and vascular oxidative stress in Alzheimer's disease. Curr Neuropharmacol (2011) 0.79
In vitro aggregation assays using hyperphosphorylated tau protein. J Vis Exp (2015) 0.79
Pharmacologic blockade of 12/15-lipoxygenase ameliorates memory deficits, Aβ and tau neuropathology in the triple-transgenic mice. Mol Psychiatry (2015) 0.79
Aggravation effect of isoflurane on Aβ(25-35)-induced apoptosis and tau hyperphosphorylation in PC12 cells. Cell Mol Neurobiol (2012) 0.79
Bioenergetics breakdown in Alzheimer's disease: targets for new therapies. Int J Physiol Pathophysiol Pharmacol (2010) 0.78
In vivo tracking of tau pathology using positron emission tomography (PET) molecular imaging in small animals. Transl Neurodegener (2014) 0.78
Microtubule-Binding Proteins as Promising Biomarkers of Paclitaxel Sensitivity in Cancer Chemotherapy. Med Res Rev (2015) 0.77
The Ambiguous Relationship of Oxidative Stress, Tau Hyperphosphorylation, and Autophagy Dysfunction in Alzheimer's Disease. Oxid Med Cell Longev (2015) 0.77
Deficiency of macrophage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer's disease. J Neuroinflammation (2015) 0.77
Intranasal Insulin Prevents Anesthesia-Induced Spatial Learning and Memory Deficit in Mice. Sci Rep (2016) 0.77
Expression of Tau protein in rats with cognitive dysfunction induced by cerebral hypoperfusion. Int J Clin Exp Med (2015) 0.77
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement (2016) 0.76
In Silico Insight into Potential Anti-Alzheimer's Disease Mechanisms of Icariin. Int J Mol Sci (2016) 0.76
Tibolone modulates neuronal plasticity through regulating Tau, GSK3β/Akt/PI3K pathway and CDK5 p35/p25 complexes in the hippocampus of aged male mice. Neural Regen Res (2017) 0.76
TFP5 prevents 1-methyl-4-phenyl pyridine ion-induced neurotoxicity in mouse cortical neurons. Exp Ther Med (2016) 0.75
Melatonin and Nitrones As Potential Therapeutic Agents for Stroke. Front Aging Neurosci (2016) 0.75
Neuroprotective Functions for the Histone Deacetylase SIRT6. Cell Rep (2017) 0.75
Specific ion channels contribute to key elements of pathology during secondary degeneration following neurotrauma. BMC Neurosci (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
A protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A (1975) 15.35
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature (2004) 11.82
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 9.30
Tau suppression in a neurodegenerative mouse model improves memory function. Science (2005) 8.66
Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science (2007) 8.56
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron (1989) 8.04
Observations on the brains of demented old people. J Neurol Sci (1970) 6.99
Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem (1997) 6.99
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem (1986) 6.91
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol (1996) 6.88
Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet (2000) 6.12
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature (1999) 5.53
Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly. J Mol Biol (1977) 4.60
GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov (2004) 3.93
Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J (2006) 3.92
Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol (1998) 3.53
Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron (1999) 3.49
Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem (1984) 3.36
Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J Cell Biol (2002) 3.35
Altered microtubule organization in small-calibre axons of mice lacking tau protein. Nature (1994) 3.20
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.18
Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci (2004) 3.05
Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95
Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res (1986) 2.77
The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem (1996) 2.73
O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 2.67
Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem (1997) 2.65
Molecular targets of lithium action. Annu Rev Pharmacol Toxicol (2001) 2.63
Developmentally regulated expression of specific tau sequences. Neuron (1989) 2.62
Identification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol (1994) 2.61
Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol (1994) 2.54
Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med (1996) 2.46
Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol (2006) 2.42
Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res (2007) 2.39
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.39
Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 2.35
Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci (2005) 2.35
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem (1993) 2.30
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci (2007) 2.24
O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors. J Biol Chem (2005) 2.22
The microtubule binding domain of tau protein. Neuron (1989) 2.17
A gene expression profile of Alzheimer's disease. DNA Cell Biol (2001) 2.16
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron (1994) 2.13
Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol (1999) 2.12
Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun (2001) 2.08
Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem (1993) 2.05
Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem (2000) 2.00
Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J Cell Biol (2000) 1.98
Tau proteins: the molecular structure and mode of binding on microtubules. J Cell Biol (1988) 1.95
Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron (1996) 1.93
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov (2007) 1.92
Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (2000) 1.92
Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem (1995) 1.86
Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci (2002) 1.82
Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm (Vienna) (2004) 1.78
Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A (1997) 1.73
The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem (1996) 1.72
Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem (2007) 1.68
C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci (2000) 1.67
Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol (2003) 1.66
Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J Neurosci (2008) 1.65
Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci (2004) 1.63
GSK-3 is essential in the pathogenesis of Alzheimer's disease. J Alzheimers Dis (2006) 1.62
Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem (2004) 1.58
Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J Neuropathol Exp Neurol (2004) 1.52
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proc Natl Acad Sci U S A (2006) 1.52
Muscle weakness, hyperactivity, and impairment in fear conditioning in tau-deficient mice. Neurosci Lett (2000) 1.51
Tau alteration and neuronal degeneration in tauopathies: mechanisms and models. Biochim Biophys Acta (2005) 1.49
Reversal of amyloid-induced heart disease in desmin-related cardiomyopathy. Proc Natl Acad Sci U S A (2005) 1.49
PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol (2001) 1.46
Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise. J Am Chem Soc (2007) 1.46
Molecular identification of I1PP2A, a novel potent heat-stable inhibitor protein of protein phosphatase 2A. Biochemistry (1996) 1.46
Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci (2006) 1.44
Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res (2005) 1.39
Up-regulation of inhibitors of protein phosphatase-2A in Alzheimer's disease. Am J Pathol (2005) 1.37
Site-specific effects of tau phosphorylation on its microtubule assembly activity and self-aggregation. Eur J Neurosci (2007) 1.36
Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J Neurochem (1995) 1.36
Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett (2006) 1.35
Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34
Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity. Proc Natl Acad Sci U S A (2006) 1.33
Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis (2003) 1.29
Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. Adv Exp Med Biol (2004) 1.29
Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem (2001) 1.28
Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci (2008) 1.28
Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments. Brain Res (1992) 1.26
Evidence of a balance between phosphorylation and O-GlcNAc glycosylation of Tau proteins--a role in nuclear localization. Biochim Biophys Acta (2003) 1.24
Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol (1987) 1.22
Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease. FEBS Lett (2008) 1.22
Disease modifying therapy for AD? J Neurochem (2006) 1.20
Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim Biophys Acta (2006) 1.20
The extent of phosphorylation of fetal tau is comparable to that of PHF-tau from Alzheimer paired helical filaments. Brain Res (1993) 1.19
Tau therapeutic strategies for the treatment of Alzheimer's disease. Curr Top Med Chem (2006) 1.16
Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci (2006) 1.16
Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now. J Alzheimers Dis (2006) 1.14
Memantine inhibits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett (2004) 1.13
Glucose metabolism and Alzheimer's disease. Ageing Res Rev (2005) 1.12
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A (1986) 10.13
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem (1986) 6.91
Abnormal fibrils from scrapie-infected brain. Acta Neuropathol (1981) 5.35
Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: a third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques. Neurosci Lett (1986) 3.36
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci U S A (2001) 2.97
Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol (1984) 2.97
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Alzheimer paired helical filaments: immunochemical identification of polypeptides. Acta Neuropathol (1984) 2.70
Alzheimer neurofibrillary tangles: monoclonal antibodies to inherent antigen(s). Acta Neuropathol (1984) 2.58
Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med (1996) 2.46
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease. Proc Natl Acad Sci U S A (1994) 2.39
Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem (1993) 2.30
Ultrastructural morphology of amyloid fibrils from neuritic and amyloid plaques. Acta Neuropathol (1983) 2.23
Evidence that Alzheimer neurofibrillary tangles originate from neurotubules. Lancet (1979) 2.22
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem (1993) 2.05
Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem (1992) 2.04
Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem (2000) 2.00
Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch Biochem Biophys (1993) 1.90
Defective brain microtubule assembly in Alzheimer's disease. Lancet (1986) 1.89
Ultrastructure of paired helical filaments of Alzheimer's neurofibrillary tangle. J Neuropathol Exp Neurol (1984) 1.86
Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem (1995) 1.86
Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm (Vienna) (2004) 1.78
Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A (1997) 1.73
Ultrastructure of the microglia that phagocytose amyloid and the microglia that produce beta-amyloid fibrils. Acta Neuropathol (1992) 1.71
Protein changes in senile dementia. Brain Res (1974) 1.65
Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol (1997) 1.63
Glycosylation of microtubule-associated protein tau: an abnormal posttranslational modification in Alzheimer's disease. Nat Med (1996) 1.57
Simulated movement termination for balance recovery: can movement strategies be sought to maintain stability in the presence of slipping or forced sliding? J Biomech (1999) 1.52
Role of feedforward control of movement stability in reducing slip-related balance loss and falls among older adults. J Neurophysiol (2003) 1.52
Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int (2006) 1.52
Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments. Brain Res (1988) 1.51
An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol (1989) 1.51
Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Arch Biochem Biophys (1998) 1.51
Lewy bodies contain epitopes both shared and distinct from Alzheimer neurofibrillary tangles. J Neuropathol Exp Neurol (1988) 1.49
Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol (1990) 1.43
Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci U S A (1989) 1.40
Alzheimer neurofibrillary tangles: antiserum and immunohistological staining. Ann Neurol (1979) 1.39
Glutamine synthetase in muscle and kidney. Biochem J (1970) 1.38
Alzheimer paired helical filaments: cross-reacting polypeptide/s normally present in brain. Acta Neuropathol (1985) 1.36
Neurofibrillary tangles in Alzheimer's disease and progressive supranuclear palsy: antigenic similarities and differences. Microtubule-associated protein tau antigenicity is prominent in all types of tangles. Acta Neuropathol (1987) 1.35
Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett (1998) 1.33
Dephosphorylation of Alzheimer paired helical filaments by protein phosphatase-2A and -2B. J Biol Chem (1995) 1.32
Factors associated with poor outcomes in patients with lupus nephritis. Lupus (2005) 1.30
Restoration of biological activity of Alzheimer abnormally phosphorylated tau by dephosphorylation with protein phosphatase-2A, -2B and -1. Brain Res Mol Brain Res (1996) 1.30
Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem (2001) 1.28
Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains. FEBS Lett (1994) 1.27
Alzheimer paired helical filaments: identification of polypeptides with monoclonal antibodies. Acta Neuropathol (1985) 1.27
Accumulation of cyclin-dependent kinase 5 (cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res (1998) 1.23
Histopathological criteria for progressive dementia disorders: clinical-pathological correlation and classification by multivariate data analysis. Acta Neuropathol (1987) 1.22
Chemical relationship of the paired helical filaments of Alzheimer's dementia to normal human neurofilaments and neurotubules. Brain Res (1978) 1.21
Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and dephosphorylation of tau by protein phosphatase 2A and 5. Neuroscience (2002) 1.19
Role of protein phosphatase-2A and -1 in the regulation of GSK-3, cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett (2000) 1.18
Detection of point mutations in codon 331 of mitochondrial NADH dehydrogenase subunit 2 in Alzheimer's brains. Biochem Biophys Res Commun (1992) 1.18
Thresholds for step initiation induced by support-surface translation: a dynamic center-of-mass model provides much better prediction than a static model. J Biomech (2000) 1.17
Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience (1994) 1.16
Abnormal phosphorylation of tau precedes ubiquitination in neurofibrillary pathology of Alzheimer disease. Brain Res (1991) 1.13
Immunochemical properties of ubiquitin conjugates in the paired helical filaments of Alzheimer disease. J Neurochem (1989) 1.12
The regulation of phosphorylation of tau in SY5Y neuroblastoma cells: the role of protein phosphatases. FEBS Lett (1998) 1.08
Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Mol Cell Biochem (1997) 1.07
Chemical pathology of neurofibrils. Neurofibrillary tangles of Alzheimer's presenile-senile dementia. J Histochem Cytochem (1975) 1.06
Immunoreactivity of neuronal lipofuscin with monoclonal antibodies to the amyloid beta-protein. Neurobiol Aging (1989) 1.04
Alzheimer's disease abnormally phosphorylated tau is dephosphorylated by protein phosphatase-2B (calcineurin). J Neurochem (1994) 1.04
Dynamic regulation of expression and phosphorylation of tau by fibroblast growth factor-2 in neural progenitor cells from adult rat hippocampus. J Neurosci (1999) 1.04
Brain aluminum in aging and Alzheimer disease. Neurology (1979) 1.04
Inhibition of PP-2A upregulates CaMKII in rat forebrain and induces hyperphosphorylation of tau at Ser 262/356. FEBS Lett (2001) 1.02
The microtubule-associated protein tau forms a triple-stranded left-hand helical polymer. J Biol Chem (1991) 1.02
Ultracytochemical distribution of myelin basic protein after injection into the cerebrospinal fluid. Evidence for transport through the blood-brain barrier and binding to the luminal surface of cerebral veins. J Neurol Sci (1984) 1.01
Inactivation of glycogen synthase kinase-3 by protein kinase C delta: implications for regulation of tau phosphorylation. FEBS Lett (2000) 1.01
Paired helical filaments associated with Alzheimer disease are readily soluble structures. Brain Res (1986) 1.00
Subcellular distribution of protein phosphatases and abnormally phosphorylated tau in the temporal cortex from Alzheimer's disease and control brains. J Neural Transm (Vienna) (1998) 0.99
Purification and characterization of two forms of Ca2+-activated neutral protease from calf brain. J Biol Chem (1983) 0.98
Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett (1996) 0.97
On neurofilament and neurotubule proteins from human autopsy tissue. J Neurochem (1977) 0.97
Morphological and chemical characterization of a starch granule-like polyglucosan deposit isolated from human brain. Acta Neuropathol (1981) 0.97
Rapid Alzheimer-like phosphorylation of tau by the synergistic actions of non-proline-dependent protein kinases and GSK-3. FEBS Lett (1995) 0.96
Mucopolysaccharidosis types IH, IS, II, and IIIA: glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues. J Neurochem (1980) 0.94
Hyperphosphorylation and accumulation of neurofilament proteins in Alzheimer disease brain and in okadaic acid-treated SY5Y cells. FEBS Lett (2001) 0.93
Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Lett (1995) 0.93
Regulation of phosphorylation of neuronal microtubule-associated proteins MAP1b and MAP2 by protein phosphatase-2A and -2B in rat brain. Brain Res (2000) 0.93
Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology (1978) 0.93
Dephosphorylation of microtubule-associated protein tau by protein phosphatase-1 and -2C and its implication in Alzheimer disease. FEBS Lett (1994) 0.92
Microtubule associated protein tau binds to double-stranded but not single-stranded DNA. Cell Mol Life Sci (2003) 0.92
Pathological profile in chronic suppurative otitis media--the regional experience. J Pak Med Assoc (1994) 0.92
The organization of the microtubule associated protein tau in Alzheimer paired helical filaments. Brain Res (1993) 0.92
Subcutaneous panniculitis-like T-cell lymphoma in association with sarcoidosis. Clin Exp Dermatol (2011) 0.91
Expression of protein phosphatases (PP-1, PP-2A, PP-2B and PTP-1B) and protein kinases (MAP kinase and P34cdc2) in the hippocampus of patients with Alzheimer disease and normal aged individuals. Brain Res (1994) 0.91
Tau and ubiquitin immunoreactivity at different stages of formation of Alzheimer neurofibrillary tangles. Prog Clin Biol Res (1989) 0.91
Ser-262 in human recombinant tau protein is a markedly more favorable site for phosphorylation by CaMKII than PKA or PhK. FEBS Lett (1998) 0.91
The encephalitogenic activity and myelin basic protein content of isolated oligodendroglia. J Neurochem (1977) 0.91
Immunocytochemical studies on neurofibrillary changes. Exp Brain Res (1982) 0.90
Aluminium and Alzheimer's disease. Lancet (1977) 0.89
Metabolically active rat brain slices as a model to study the regulation of protein phosphorylation in mammalian brain. Brain Res Brain Res Protoc (2001) 0.89
Post-translational modifications of tau protein. Bratisl Lek Listy (2006) 0.89
The solubility controversy of paired helical filaments: a commentary. Neurochem Res (1987) 0.88
Sialosylgalactosyl ceramide as a specific marker for human myelin and oligodendroglial perikarya: gangliosides of human myelin, oligodendroglia and neurons. J Neurochem (1979) 0.88
PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. J Neural Transm (Vienna) (2005) 0.87
Phosphorylation of tau protein by casein kinase-1 converts it to an abnormal Alzheimer-like state. J Neurochem (1995) 0.87
Hypercalcemia in childhood renal tumors. Cancer (1988) 0.87